Trial Profile
A dose exploration study of Favipiravir for the treatment of COVID-19 infection
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Mar 2020
At a glance
- Drugs Favipiravir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Acronyms TRIALS
- 09 Mar 2020 New trial record
- 02 Mar 2020 According to a Sihuan Pharmaceutical media release, the Trials study was officially initiated by the Ministry of Science and Technology in early February.
- 02 Mar 2020 According to the Sihuan Pharmaceutical media release, the Trials study is led by Beijing Chaoyang Hospital affiliated with Capital Medical University, with Professor Tong Zhaohui as the leading researcher. Another two research centers include Union Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology and Wuhan Jinyintan Hospital.
Most Recent Events
Trial Overview
Purpose
This dose exploration study will assess the best regimen of Favipiravir for the treatment of Corona virus disease 2019 (COVID-19).
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
-
Number
Actual: 60
- Sex male & female
Patient Inclusion Criteria
Subjects with COVID-19 infection
Trial Details
Organisations
- Affiliations Sihuan Pharmaceutical Holdings Group
Trial Dates
-
Initiation Dates
Actual : 01 Feb 2020
Other Details
- Design multicentre; parallel; prospective; randomised
- Phase of Trial Phase I
- Location China
- Focus Adverse reactions
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| FavipiravirPrimary Drug | Oral |
-
|
Favipiravir
Patients will be recruited for a treatment period of 10 days
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 09 Mar 2020 | New trial record | New trial record Updated 09 Mar 2020 |
| 02 Mar 2020 | Other trial event | According to a Sihuan Pharmaceutical media release, the Trials study was officially initiated by the Ministry of Science and Technology in early February. Updated 09 Mar 2020 |
| 02 Mar 2020 | Other trial event | According to the Sihuan Pharmaceutical media release, the Trials study is led by Beijing Chaoyang Hospital affiliated with Capital Medical University, with Professor Tong Zhaohui as the leading researcher. Another two research centers include Union Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology and Wuhan Jinyintan Hospital. Updated 09 Mar 2020 |
References
-
Sihuan Pharmaceutical Holdings Group. Sihuan Pharmaceutical Announces Clinical Research of Favipiravir, A Drug for Coronavirus Disease 2019, Co-Developed with the Academy of Military Medical Sciences of the People's Liberation Army, Has Commenced. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG